IEHP UM Subcommittee Approved Authorization Guidelines
Iontophoresis for Hyperhidrosis

Policy:
IEHP considers treatment of intractable disabling primary hyperhidrosis with iontophoresis (electrophoresis, Drionic device) medically necessary when all of the following criteria are met:

1. Topical aluminum chloride or other extra-strength antiperspirants are ineffective or result in severe rash; and
2. Member is unresponsive or unable to tolerate pharmacotherapy prescribed for excessive sweating (e.g., Drysol, anti-cholinergics, beta-blockers, benzodiazepines) if sweating is episodic; and
3. Significant disruption of professional and/or social life has occurred because of excessive sweating.

Background:
Hyperhidrosis is defined as a condition of excessive sweating beyond what is necessary for thermal regulation. Hyperhidrosis can be classified as either primary or secondary. Primary localized hyperhidrosis is idiopathic and typically involving hands (palmar), feet (plantar), or axillary. Secondary hyperhidrosis may be result of variety of medications or underlying disease/conditions and typically is generalized or craniofacial.

Iontophoresis is the introduction of ionizable drugs through intact skin by administration of continuous, direct electrical current into the tissue.

Effective Date: May 24, 2007
Reviewed Annually: November 9, 2016
Revised: 9/8/2015
November 11, 2015
Bibliography:

5. Medical Review Criteria Guidelines for Managing Care, Dermatology DER 120, Hyperhidrosis, Volume I, part 1, pg186
Disclaimer

IEHP Clinical Authorization Guidelines (CAG) are developed to assist in administering plan benefits, they do not constitute a description of plan benefits. The Clinical Authorization Guidelines (CAG) express IEHP’s determination of whether certain services or supplies are medically necessary, experimental and investigational, or cosmetic. IEHP has reached these conclusions based upon a review of currently available clinical information (including clinical outcome studies in the peer-reviewed published medical literature, regulatory status of the technology, evidence-based guidelines of public health and health research agencies, evidence-based guidelines and positions of leading national health professional organizations, views of physicians practicing in relevant clinical areas, and other relevant factors). IEHP makes no representations and accepts no liability with respect to the content of any external information cited or relied upon in the Clinical Authorization Guidelines (CAG). IEHP expressly and solely reserves the right to revise the Clinical Authorization Guidelines (CAG), as clinical information changes.